Application of FDG-PET in cervical cancer and endometrial cancer: utility and future prospects.
Yuya Nogami(Keio University), Daisuke Aoki(International University of Health and Welfare), Miho Iida(Keio University), Kyoko Tanaka(Keio University), Iori Kisu(Fujita Health University), Kouji Banno(Keio University), Masataka Adachi(Keio University), Eiichiro Tominaga(Keio University), Kenta Masuda(Keio University), Kiyoko Umene(Keio University), K. Nakamura(Teikyo Heisei University)
PubMed
February 1, 2014
Cited by 41
Related Papers
Pathological Steps of Cancer-Related Lymphedema: Histological Changes in the Collecting Lymphatic Vessels after Lymphadenectomy
|PLoS ONE|2012|331
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|214
MicroRNA in Cervical Cancer: OncomiRs and Tumor Suppressor miRs in Diagnosis and Treatment
|The Scientific World JOURNAL|2014|143
Cross‐sectional analysis of germline <i>BRCA</i>1 and <i>BRCA</i>2 mutations in Japanese patients suspected to have hereditary breast/ovarian cancer
|Cancer Science|2008|105
Registry of the International Society of Uterus Transplantation: First Report
|Transplantation|2022|100